Aiming to transform cancer care by developing curative allogeneic cell therapies
PRESS RELEASES + EVENTS view all
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
– Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits…
We are building a fully integrated biotechnology company that is developing transformational next generation iPSC-derived iNK and iT cell therapies for hematological and solid tumor malignancies.
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.